Page last updated: 2024-11-02

oxybutynin and Bonnevie-Ullrich Syndrome

oxybutynin has been researched along with Bonnevie-Ullrich Syndrome in 2 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Bonnevie-Ullrich Syndrome: This syndrome that was originally observed by Ullrich, and designated as identical to TURNER SYNDROME, related the webbing of the neck, loose skin and other anomalies of the syndrome to accumulation of fluid in the embryo starting at the head and dispersing to the extremities (as observed by Bonnevie in mice). Commonly observed at birth in Turner Syndrome and NOONAN SYNDROME; EDEMA of the extremities usually recedes by one year and is an early sign of Turner syndrome, especially in female neonates.

Research Excerpts

Excerpt	Relevance	Reference
"Our objective was to assess metabolic effects of oral vs transdermal (TD) 17β-E₂ replacement using estrogen concentration-based dosing in girls with Turner syndrome (TS)."	2.78	Metabolic effects of oral versus transdermal 17β-estradiol (E₂): a randomized clinical trial in girls with Turner syndrome. ( Hossain, J; Klein, KO; Mauras, N; Mericq, V; Ross, JL; Santen, RJ; Singh, R; Taboada, M; Torres-Santiago, L; Unanue, N, 2013)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Torres-Santiago, L	2
Mericq, V	1
Taboada, M	2
Unanue, N	1
Klein, KO	1
Singh, R	1
Hossain, J	1
Santen, RJ	1
Ross, JL	1
Mauras, N	2
Santen, R	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism[NCT00837616]			Phase 4	41 participants (Actual)	Interventional	2009-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Body Mass Index From Baseline at 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	kg/m2 (Mean)
Oral Estradiol	0.075
Transdermal Estradiol	0.65

Change in Fat Free Mass From Baseline at 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	kg (Mean)
Oral Estradiol	1.03
Transdermal Estradiol	1.67

Change in Percent Fat Mass From Baseline in 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	percent fat mass (Mean)
Oral Estradiol	-0.14
Transdermal Estradiol	-0.64

Change in Weight From Baseline at 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	kilograms (Mean)
Oral Estradiol	1.1
Transdermal Estradiol	1.9

Changes in Insulin Growth Factor-I From Baseline at 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	ng/ml (Mean)
Oral Estradiol	-16
Transdermal Estradiol	28

Rates of Lipid Oxidation After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	Kcal/Fat Free Mass/day (Mean)
Oral Estradiol	10
Transdermal Estradiol	7.3

Serum 17B Estradiol Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	pg/ml (Mean)
Oral Estradiol	124
Transdermal Estradiol	74

Serum Estrone Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	pg/mL (Mean)
Oral Estradiol	504
Transdermal Estradiol	43

Serum Estrone Sulfate Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	pg/mL (Mean)
Oral Estradiol	63638
Transdermal Estradiol	1875

Lipids Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months

(NCT00837616)
Timeframe: 12 months

Intervention	mg/dl (Mean)
	Total Cholesterol	Low Density Lipoprotein	High Density Lipoprotein	Triglycerides
Oral Estradiol	168	93	56	95
Transdermal Estradiol	153	88	50	70

Reviews

1 review available for oxybutynin and Bonnevie-Ullrich Syndrome

Article	Year
Estrogen therapy in Turner syndrome: does the type, dose and mode of delivery matter? Pediatric endocrinology reviews : PER, 2012, Volume: 9 Suppl 2 Topics: Administration, Cutaneous; Administration, Oral; Child; Estradiol; Estrogen Replacement Therapy; Est	2012

Trials

1 trial available for oxybutynin and Bonnevie-Ullrich Syndrome

Article	Year
Metabolic effects of oral versus transdermal 17β-estradiol (E₂): a randomized clinical trial in girls with Turner syndrome. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Basal Metabolism; Biotransformation; Body Composition; Bone	2013